APREA THERAPEUTICS INC (APRE) Fundamental Analysis & Valuation

NASDAQ:APRE • US03836J2015

Current stock price

0.7154 USD
+0.01 (+1.65%)
At close:
0.68 USD
-0.04 (-4.95%)
After Hours:

This APRE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. APRE Profitability Analysis

1.1 Basic Checks

  • In the past year APRE has reported negative net income.
  • In the past year APRE has reported a negative cash flow from operations.
  • APRE had negative earnings in each of the past 5 years.
  • In the past 5 years APRE always reported negative operating cash flow.
APRE Yearly Net Income VS EBIT VS OCF VS FCFAPRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • APRE has a Return On Assets of -91.04%. This is in the lower half of the industry: APRE underperforms 72.53% of its industry peers.
  • Looking at the Return On Equity, with a value of -112.02%, APRE is in line with its industry, outperforming 41.78% of the companies in the same industry.
Industry RankSector Rank
ROA -91.04%
ROE -112.02%
ROIC N/A
ROA(3y)-163.39%
ROA(5y)-122.63%
ROE(3y)-186.11%
ROE(5y)-140.49%
ROIC(3y)N/A
ROIC(5y)N/A
APRE Yearly ROA, ROE, ROICAPRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • APRE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APRE Yearly Profit, Operating, Gross MarginsAPRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. APRE Health Analysis

2.1 Basic Checks

  • APRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, APRE has more shares outstanding
  • APRE has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for APRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APRE Yearly Shares OutstandingAPRE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
APRE Yearly Total Debt VS Total AssetsAPRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • APRE has an Altman-Z score of -34.50. This is a bad value and indicates that APRE is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of APRE (-34.50) is worse than 90.52% of its industry peers.
  • APRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.5
ROIC/WACCN/A
WACC9.19%
APRE Yearly LT Debt VS Equity VS FCFAPRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 5.20 indicates that APRE has no problem at all paying its short term obligations.
  • APRE has a Current ratio of 5.20. This is comparable to the rest of the industry: APRE outperforms 57.06% of its industry peers.
  • A Quick Ratio of 5.20 indicates that APRE has no problem at all paying its short term obligations.
  • APRE has a Quick ratio of 5.20. This is comparable to the rest of the industry: APRE outperforms 58.03% of its industry peers.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
APRE Yearly Current Assets VS Current LiabilitesAPRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. APRE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.35% over the past year.
  • APRE shows a strong growth in Revenue. In the last year, the Revenue has grown by 157.65%.
EPS 1Y (TTM)40.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.69%
Revenue 1Y (TTM)157.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.38%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.08% on average over the next years. This is quite good.
  • APRE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 105.20% yearly.
EPS Next Y14.71%
EPS Next 2Y22.3%
EPS Next 3Y17.86%
EPS Next 5Y18.08%
Revenue Next Year-78.07%
Revenue Next 2Y-41.42%
Revenue Next 3Y-7.16%
Revenue Next 5Y105.21%

3.3 Evolution

APRE Yearly Revenue VS EstimatesAPRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
APRE Yearly EPS VS EstimatesAPRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. APRE Valuation Analysis

4.1 Price/Earnings Ratio

  • APRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year APRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APRE Price Earnings VS Forward Price EarningsAPRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APRE Per share dataAPRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as APRE's earnings are expected to grow with 17.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.3%
EPS Next 3Y17.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. APRE Dividend Analysis

5.1 Amount

  • No dividends for APRE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APRE Fundamentals: All Metrics, Ratios and Statistics

APREA THERAPEUTICS INC

NASDAQ:APRE (4/2/2026, 8:08:13 PM)

After market: 0.68 -0.04 (-4.95%)

0.7154

+0.01 (+1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)05-12
Inst Owners20.4%
Inst Owner Change4.83%
Ins Owners20.03%
Ins Owner Change1.58%
Market Cap5.00M
Revenue(TTM)1.50M
Net Income(TTM)-13.04M
Analysts84.44
Price Target5.44 (660.41%)
Short Float %2%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.94%
Min EPS beat(2)-36.13%
Max EPS beat(2)30.25%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-38.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.38%
EPS NY rev (1m)-26.94%
EPS NY rev (3m)-19.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.24
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.93
FCFYN/A
OCF(TTM)-1.93
OCFYN/A
SpS0.07
BVpS1.67
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -91.04%
ROE -112.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-163.39%
ROA(5y)-122.63%
ROE(3y)-186.11%
ROE(5y)-140.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z -34.5
F-Score1
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.69%
EPS Next Y14.71%
EPS Next 2Y22.3%
EPS Next 3Y17.86%
EPS Next 5Y18.08%
Revenue 1Y (TTM)157.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.38%
Revenue Next Year-78.07%
Revenue Next 2Y-41.42%
Revenue Next 3Y-7.16%
Revenue Next 5Y105.21%
EBIT growth 1Y6.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.71%
EBIT Next 3Y-4.7%
EBIT Next 5Y-10.25%
FCF growth 1Y-7.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.27%
OCF growth 3YN/A
OCF growth 5YN/A

APREA THERAPEUTICS INC / APRE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for APREA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to APRE.


What is the valuation status for APRE stock?

ChartMill assigns a valuation rating of 0 / 10 to APREA THERAPEUTICS INC (APRE). This can be considered as Overvalued.


Can you provide the profitability details for APREA THERAPEUTICS INC?

APREA THERAPEUTICS INC (APRE) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for APRE stock?

The Earnings per Share (EPS) of APREA THERAPEUTICS INC (APRE) is expected to grow by 14.71% in the next year.